Categories: CancerDiagnosticsNews

EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Company to host conference call and webcast on Thursday, August 25that 8:30 am EDT

LYON, France, August 3, 2022 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30th after the markets close on Wednesday, August 24th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, August 25th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, August 25th@ 8:30am Eastern Time
Domestic:        877-451-6152
International:        201-389-0879
Passcode:        13731177
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1558239&tp_key=295933838c

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com

 

Staff

Recent Posts

ZEISS and LG Chem join forces to strengthen the photopolymer supply chain for advanced optics

ZEISS and LG Chem established a strategic framework for industrial-scale photopolymer film supply in advanced…

3 hours ago

Quantum BioPharma Ltd. Announces Corporate Updates

Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)…

6 hours ago

Dräger achieves perfect-score CMMC Level 2 Certification reinforcing cybersecurity leadership in Defense and Government healthcare and safety technology

Certification ensures the highest level of data security for mission-critical medical and safety technology TELFORD,…

9 hours ago

Waystar Reports Third Quarter 2025 Results

Q3 revenue growth of 12% year-over-year Q3 net income of $30.6 million and non-GAAP net…

9 hours ago

PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth

PatientNow, the leader in practice management and growth technology for aesthetics practices, today announced the…

9 hours ago